Genasys Revenue Jumps 37.5% Amidst Rising Costs, Mounting Debt

TL;DR

**Genasys is growing revenue but drowning in debt and costs, making it a risky bet despite market demand.**

AI Summary

Genasys Inc. reported a net loss of $6.487 million for the three months ended June 30, 2025, a slight improvement from the $6.682 million net loss in the prior-year period. Total revenues increased significantly by 37.5% to $9.857 million for the quarter, up from $7.167 million, driven by a 53% surge in product sales to $7.001 million. However, cost of revenues more than doubled to $7.260 million from $3.383 million, leading to a 31.4% decrease in gross profit to $2.597 million. Operating expenses decreased slightly by 6.8% to $8.522 million. For the nine months ended June 30, 2025, the net loss was $16.704 million, an improvement from $20.344 million in the same period last year, while total revenues grew 37.4% to $23.729 million. The company's current liabilities dramatically increased to $49.395 million from $14.085 million at September 30, 2024, primarily due to $17.050 million in short-term notes payable and a significant rise in accrued liabilities to $23.473 million. Cash and cash equivalents increased to $5.339 million from $4.945 million.

Why It Matters

Genasys's substantial revenue growth, particularly in product sales, suggests increasing market demand for its Protective Communications solutions, which could be a positive signal for investors. However, the sharp increase in cost of revenues and the dramatic rise in current liabilities, including $17.050 million in short-term notes payable, raise significant concerns about profitability and liquidity. This financial strain could impact the company's ability to invest in R&D, retain employees, or expand its customer base, potentially hindering its competitive position against larger players in the public safety and enterprise threat management market. The market will be watching to see if Genasys can translate revenue growth into sustainable profitability and manage its debt obligations.

Risk Assessment

Risk Level: high — The company's current liabilities surged to $49.395 million as of June 30, 2025, from $14.085 million at September 30, 2024, primarily driven by $17.050 million in short-term notes payable. This significant increase in short-term debt, coupled with a net loss of $6.487 million for the quarter and a 31.4% decrease in gross profit, indicates substantial liquidity and profitability challenges. The company's ability to meet these short-term obligations is a major concern.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate Genasys's ability to manage its rapidly increasing short-term debt and improve gross margins. Await clearer signs of sustainable profitability and debt reduction before considering an investment, as the current financial structure presents significant risk.

Financial Highlights

revenue

$9.857M

net Income

-$6.487M

eps

-$0.14

gross Margin

26.35%

cash Position

$5.339M

revenue Growth

+37.5%

Revenue Breakdown

Key Numbers

• $9.857M — Total Revenues (Q3 2025) (Increased 37.5% from $7.167M in Q3 2024)
• $7.001M — Product Sales (Q3 2025) (Increased 53% from $4.576M in Q3 2024)
• $6.487M — Net Loss (Q3 2025) (Slight improvement from $6.682M net loss in Q3 2024)
• $7.260M — Cost of Revenues (Q3 2025) (More than doubled from $3.383M in Q3 2024)
• $2.597M — Gross Profit (Q3 2025) (Decreased 31.4% from $3.784M in Q3 2024)
• $17.050M — Short-term Notes Payable (New liability as of June 30, 2025, compared to zero at Sep 30, 2024)
• $49.395M — Total Current Liabilities (Increased from $14.085M at Sep 30, 2024)
• $5.339M — Cash and Cash Equivalents (Increased from $4.945M at Sep 30, 2024)
• $0.14 — Net Loss Per Share (Q3 2025) (Improved from $0.15 in Q3 2024)
• 45,154,504 — Common Shares Outstanding (As of August 8, 2025)

Key Players & Entities

• Genasys Inc. (company) — global provider of Protective Communications solutions
• Evertel Technologies LLC (company) — acquired by Genasys Inc. on October 4, 2023
• NASDAQ Capital Market (regulator) — exchange where Genasys Inc. common stock is registered
• Securities and Exchange Commission (regulator) — regulates financial reporting for Genasys Inc.
• $9.857 million (dollar_amount) — total revenues for the three months ended June 30, 2025
• $7.001 million (dollar_amount) — product sales for the three months ended June 30, 2025
• $6.487 million (dollar_amount) — net loss for the three months ended June 30, 2025
• $17.050 million (dollar_amount) — short-term notes payable as of June 30, 2025
• $49.395 million (dollar_amount) — total current liabilities as of June 30, 2025
• $5.339 million (dollar_amount) — cash and cash equivalents as of June 30, 2025

FAQ

Risk Factors

• Deteriorating Gross Margins [high — financial]: Cost of revenues more than doubled to $7.260 million from $3.383 million in Q3 2025, leading to a 31.4% decrease in gross profit to $2.597 million. This indicates a significant challenge in managing the cost of goods sold relative to revenue.
• Increasing Current Liabilities [high — financial]: Total current liabilities dramatically increased to $49.395 million from $14.085 million at September 30, 2024. This surge is primarily due to $17.050 million in new short-term notes payable and a significant rise in accrued liabilities to $23.473 million, raising concerns about short-term liquidity.
• Persistent Net Losses [medium — operational]: The company reported a net loss of $6.487 million for Q3 2025, and $16.704 million for the nine months ended June 30, 2025. While there's a slight improvement year-over-year, the continued unprofitability poses a long-term sustainability risk.
• High Operating Expenses [medium — financial]: Operating expenses decreased slightly by 6.8% to $8.522 million in Q3 2025, but remain substantial relative to gross profit, contributing to the net loss.

Industry Context

Genasys Inc. operates in a competitive landscape where revenue growth is achievable, as demonstrated by their 37.5% increase. However, the industry likely faces pressures on cost management and supply chain efficiency, as evidenced by Genasys's doubling cost of revenues.

Regulatory Implications

As a publicly traded company, Genasys Inc. is subject to SEC reporting requirements. The significant increase in short-term debt and accrued liabilities may attract scrutiny regarding financial stability and compliance with debt covenants.

What Investors Should Do

1. Monitor Cost of Revenues closely.
2. Analyze the nature of the new short-term notes payable and accrued liabilities.
3. Evaluate the sustainability of revenue growth against cost pressures.

Key Dates

• 2025-06-30: End of Q3 2025 — Reporting period for the latest financial results, showing revenue growth but declining gross profit and increasing liabilities.
• 2024-09-30: End of Fiscal Year 2024 — Prior period balance sheet comparison point, highlighting a significant increase in current liabilities and short-term debt.

Glossary

Cost of Revenues

The direct costs attributable to the production or purchase of the goods sold by a company. (A significant increase in this cost for Genasys Inc. is directly impacting its gross profit margins.)

Accrued Liabilities

Expenses that have been incurred but not yet paid. (A substantial rise in accrued liabilities to $23.473 million is a major contributor to the increase in total current liabilities.)

Short-term Notes Payable

Debt that is due within one year. (The addition of $17.050 million in short-term notes payable is a key driver of the increased current liabilities.)

Gross Profit

Revenue minus the cost of goods sold. (Genasys Inc. experienced a significant decrease in gross profit, indicating challenges in managing production or procurement costs relative to sales.)

Year-Over-Year Comparison

Genasys Inc. reported a 37.5% increase in total revenues to $9.857 million for the quarter ended June 30, 2025, compared to the prior year. However, this top-line growth was overshadowed by a more than doubling of the cost of revenues, leading to a 31.4% decrease in gross profit. The company also saw a dramatic increase in current liabilities, rising from $14.085 million to $49.395 million, largely due to new short-term debt and higher accrued liabilities, while net losses saw a slight improvement.

Key Financial Figures

• $0.00001 — curities are registered Common stock, $0.00001 par value per share GNSS NASDAQ Cap

Filing Documents

• gnss-20250630.htm (10-Q) — 3713KB
• gnss-ex31_1.htm (EX-31.1) — 15KB
• gnss-ex31_2.htm (EX-31.2) — 15KB
• gnss-ex32_1.htm (EX-32.1) — 12KB
• img38272234_0.jpg (GRAPHIC) — 7KB
• 0000950170-25-109006.txt ( ) — 16038KB
• gnss-20250630.xsd (EX-101.SCH) — 1599KB
• gnss-20250630_htm.xml (XML) — 3986KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Comprehensive Loss 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Unaudited Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 39 PART II. OTHER INFORMATION 40 Item 1.

Legal Proceedings

Legal Proceedings 40 Item 1A.

Risk Factors

Risk Factors 40 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41 Item 3. Defaults Upon Senior Securities 41 Item 4. Mine Safety Disclosures 41 Item 5. Other Information 41 Item 6. Exhibits 42

FINAN CIAL INFORMATION

PART I. FINAN CIAL INFORMATION

Finan cial Statements

Item 1. Finan cial Statements Genasys Inc. CONDENSED CONSOLID ATED BALANCE SHEETS (in thousands, except par value and share amounts) June 30, 2025 September 30, 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 5,339 $ 4,945 Short-term marketable securities 120 7,945 Restricted cash 95 95 Accounts receivable, net of allowance for credit losses of $ 65 4,648 3,283 Contract assets 2,846 — Inventories, net 11,426 7,313 Prepaid expenses and other 7,458 2,559 Total current assets 31,932 26,140 Long-term marketable securities — 249 Long-term restricted cash 585 250 Property and equipment, net 1,169 1,291 Goodwill 13,451 13,329 Intangible assets, net 6,724 8,506 Operating lease right of use assets, net 2,550 3,110 Other assets 982 1,061 Total assets $ 57,393 $ 53,936 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 7,797 $ 4,034 Accrued liabilities 23,473 9,030 Operating lease liabilities, current portion 1,075 1,021 Notes payable, at fair value - short term 17,050 — Total current liabilities 49,395 14,085 Notes payable, at fair value - long term — 12,010 Warrant liability 2,080 6,640 Deferred revenue, noncurrent 294 369 Operating lease liabilities, noncurrent 2,465 3,269 Total liabilities 54,234 36,373 Stockholders' equity: Preferred stock, $ 0.00001 par value; 5,000,000 shares authorized; none issued and outstanding — — Common stock, $ 0.00001 par value; 100,000,000 shares authorized; 45,154,504 and 44,631,030 shares issued and outstanding as of June 30, 2025 and September 30, 2024, respectively — — Additional paid-in capital 126,979 125,690 Accumulated deficit ( 124,496 ) ( 107,792 ) Accumulated other comprehensive income (loss) 676 ( 335 ) Total stockholders' equity 3,159 17,563 Total liabiliti

View Full Filing

View this 10-Q filing on SEC EDGAR